Moscow Exchange · PRMD · IFRS
Promomed: revenue, profit and cash flow
In 2025, Promomed had revenue of ₽37.6B and a net profit of ₽7.04B, according to its consolidated IFRS statements. Here: 4 years of annual reports since 2022, each linked to the original document.
Revenue, 2025
change against 2024
Where the money goes
Of every ₽100 of revenue in 2025, Promomed spent ₽32.3 on the cost of its products and services and ₽31.1 on running the business (₽30.2 of it on selling and administration); ₽6.9 went to income tax, ₽10.9 went to interest and other items, and ₽18.7 was left as net profit.
| In 2025 | Amount | Of revenue |
|---|---|---|
| Revenue | ₽37.6B | 100.0% |
| Cost of revenue | −₽12.2B | 32.3% |
| Gross profit | ₽25.4B | 67.7% |
| Sales & admin | −₽11.4B | 30.2% |
| Other operating | −₽339M | 0.9% |
| Operating profit | ₽13.7B | 36.5% |
| Income tax | −₽2.59B | 6.9% |
| Interest and other, net | −₽4.1B | 10.9% |
| Net profit | ₽7.04B | 18.7% |
In 2025, Promomed took in ₽267M of cash from its operations. Of every ₽100 of it, it spent ₽699.4 on capital expenditure, ₽150.8 on dividends and ₽288.1 on buying back its own shares. In all, it paid out ₽2.78B more than its operations brought in; the difference came from borrowing, cash on hand or investments it sold.
| In 2025 | Amount | Of operating cash |
|---|---|---|
| Operating cash flow | ₽267M | 100.0% |
| Capital expenditure | −₽1.87B | 699.4% |
| Free cash flow | −₽1.6B | 599.4% |
| Dividends | −₽403M | 150.8% |
| Buybacks | −₽770M | 288.1% |
| Left over | −₽2.78B | 1,038.4% |
Revenue and net profit
Revenue went from ₽13.5B in 2022 to ₽37.6B in 2025.
Earnings per share
Basic earnings per share went from ₽19.88 in 2022 to ₽35.26 in 2025.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was −₽1.6B in 2025, −4.3% of revenue. Negative in 2022–2025.
What it owns and who paid for it
At the end of 2025, Promomed had ₽71B of assets, ₽4.21B of it in cash. They were paid for by ₽28.4B of borrowings, ₽16.2B of other liabilities and ₽26.3B of shareholders' equity: equity is 37.1% of the assets.
Net debt
Net debt (borrowings minus cash) was ₽24.2B at the end of 2025. That is 1.6 times its EBITDA of ₽15.1B (operating profit plus depreciation and amortisation).
Dividends paid
In 2025, Promomed paid ₽403M in dividends, 6% of its net profit for the year.
The charts could not be loaded; the table below has the same numbers.
Promomed: annual figures
| Year | Revenue | Operating profit | Net profit | Basic EPS | Operating cash flow | Capital expenditure | Free cash flow | Net debt | Dividends paid | Total assets | Equity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₽37.6B | ₽13.7B | ₽7.04B | ₽35.26 | ₽267M | ₽1.87B | −₽1.6B | ₽24.2B | ₽403M | ₽71B | ₽26.3B |
| 2024 | ₽21.4B | ₽6.9B | ₽2.86B | ₽13.94 | ₽93M | ₽2.65B | −₽2.56B | ₽16.4B | ₽346M | ₽53.1B | ₽19.3B |
| 2023 | ₽15.8B | ₽5.6B | ₽2.99B | ₽14.95 | −₽1.19B | ₽2.9B | −₽4.09B | ₽15.6B | ₽174M | ₽34.8B | ₽13B |
| 2022* | ₽13.5B | ₽5.35B | ₽3.98B | ₽19.88 | ₽2.96B | ₽4.63B | −₽1.67B | ₽9.03B | ₽601M | ₽25.9B | ₽10.3B |
* Taken from the comparative column of the next year's report: the year's own report was not available to us.
Original reports
Every figure on this page comes from the company's own annual statements. The documents, by year:
How to read these numbers
- A year's figures are as first reported. Companies sometimes restate the previous year in their next report (new accounting standards, discontinued operations); the original documents show both versions.
Source: annual financial statements published by Promomed (links to the original documents above). Figures read from the documents by BigCapital.
For information only, not investment advice.